Eric Schmidt

Interview Summary & Key Takeaways: Biotech’s 80% XBI rally is structurally M&A-led, with roughly $138B announced against $59B of equity issuance, compressing premiums and leaving no preclinical IPOs. Moderna’s melanoma vaccine suggests a durable trade-secret franchise, while BioNTech’s colorectal failure leaves tumor context unresolved; daraxonrasib’s $478K price and frontline label, and ivonescimab’s HARMONi-3 in 6–9 months, set the key monitoring points.

• 🔗 Original source & video: Episode 194 - August 28, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

• Biotech’s rally is real but structurally different from the 2021 peak: XBI up ~80% over 12 months vs. the S&P’s ~20%, yet the plumbing underneath has inverted. Daphne Zohar’s numbers: ~$138B of M&A announced YTD against only ~$59B of equity issuance (vs. a balanced $67B/$66B at the last peak), 20 IPOs vs. nine in 2025, and — tellingly — no preclinical IPO this cycle vs. 19 in the year before the last top. Big pharma’s ~$180B patent cliff through 2032 keeps the bid, even as takeout premiums compress.

• Moderna’s individualized neoantigen vaccine hit recurrence-free and distant-metastasis-free survival in resected melanoma, sending the stock from the $50–60 range to over $170 on August 19 (settled ~$140). Sam Fazeli’s sum-of-parts gets to ~$12B “if everything worked, not risk-adjusted” — with half shared by Moderna in some fashion — versus what the market is now paying, and the company led a $2.6B convertible offering. Eric Schmidt’s durability kicker: the neoantigen-selection algorithm is likely a trade secret, so “there will never be a generic form of this vaccine… a forever franchise.”

• BioNTech’s colorectal vaccine failure the same week brackets the class rather than refuting it. Sam’s framing: “melanoma having worked, hottest tumor, colorectal had a problem, coldest tumor. What happens in the middle?” — with Moderna’s adjuvant RCC readout expected by year-end as the next data point.

• Sam publicly flipped bullish on Akeso/Summit’s ivonescimab after headline PFS and OS efficacy in biliary tract cancer — a tumor where Roche’s Tecentriq-plus-Avastin combination had failed to show an OS benefit. “Something’s going on here that is different… it has to be” than PD-1 plus VEGF. Eric: most clients remain “glass half empty,” so a positive HARMONi-3 in ~6–9 months would send Summit “through the roof” — the same entrenched-skepticism setup that powered Moderna.

• Revolution Medicines’ daraxonrasib (RMC-6236) won pancreatic-cancer approval in just over a month — priced at $478K/year vs. Sam’s $275K assumption, and with a label wedge into frontline. Eric (a former RVMD board member) flags that approval for patients ineligible for multi-agent chemo means frontline drift — “I’d be asking for daraxonrasib as a frontline agent” — which will make first- and second-line trials brutal for follow-on RAS and PRMT5 programs.

• The Heidi Overton FDA nomination splits the panel: pro-innovation talking points vs. thin management credentials and MAHA baggage. Graig Suvannavejh sees rare disease, neuro, cell therapy and psychedelics as potential winners; Eric calls her “a bit of a Dr. Makary clone” and, after measles deaths in Pennsylvania, says he’d “hate to see yet another healthcare leader appointed who shares any of those views.” Daphne on Cassidy’s objections: he talked a lot before RFK’s appointment but supported it afterward — “I don’t really put a lot of weight into what he says.”

• China policy is hardening beyond the usual hawks: US INDs are down >10% since 2020 while China’s Phase 1 count nearly doubled (~600 to 1,100+), and now a Moolenaar–Cline letter wants China-generated data rejected absent a site audit within the prior year. Sam accepts Western manufacturing and Western/US trials “given the current geopolitics,” but says crimping deals with Chinese biotechs “just does not make any sense to me.” Eric argues against blanket restrictions and says to “just let the market make its decisions”; he describes US versus China/Korea IPO performance and capital raised as “chalk and cheese.”

• Negative readouts and premium pricing carried the back half: eplontersen’s CARDIO-TTRansform showed adding a silencer to a stabilizer in ATTR-CM gave no benefit and “a little bit worse” outcomes, so expect less combo use — a read-through to Alnylam’s vutrisiran that Sam says John Maraganore disputes; EyePoint fell 70%+ on its wet-AMD miss with a second Phase 3 due in October; Amylyx’s avexitide hit with a p-value containing at least four, perhaps five, zeros and raised $500M+. Meanwhile Priovant’s brepocitinib launch price of a little over $400K for dermatomyositis fed a debate that ended with a warning that US healthcare and drug costs are “a ticking time bomb.”

• 🔗 Original source & video: Episode 194 - August 28, 2026

Interview Summary & Key Takeaways: AstraZeneca’s eplontersen failed its ATTR cardiomyopathy outcomes trial, with Ionis reporting no benefit in the tafamidis-combination group, including no CV-biomarker effect. The readout improves Alnylam’s perception, but royalty-free Nucresiran must still show whether its adjunctive outcomes study preserves silencer-plus-tafamidis synergy; Agios’ mitapivat won priority review despite missing its co-primary VOC endpoint. Atumelnant’s liver-enzyme elevations remain a risk to monitor.

• 🔗 Original source & video: Episode 188 - July 10, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

• The week’s biggest tradeable shock: AstraZeneca’s eplontersen failed its ATTR cardiomyopathy outcomes trial, and Sam Fazeli reported from Ionis that in the tafamidis-combination group “no benefit means no benefit” — nothing on secondary endpoints or even CV biomarkers. Alnylam opened up ~17% on the perception that it now owns the silencer market, but Sam flags the catch: Amvuttra pays Sanofi a 20–30% royalty, so royalty-free Nucresiran must succeed — and its largely adjunctive outcomes study now faces a direct question about whether this readout undermines silencer-plus-tafamidis synergy. Josh Schimmer says some observers think another positive TTR cardiomyopathy readout may never come.

• The FDA is quietly re-sealing complete response letters: none have been released since April, coinciding with a Covington & Burling citizen petition arguing publication breaches sponsors’ confidential information. Matt Herper calls CRL transparency “one of the best things” Makary did while noting Makary’s habit of “not really worrying about legality” first; meanwhile Rick Pazdur is “definitely in the mix” to return, though Herper cautions he’d want “some substantial control” and the administration “hasn’t loved people who are critical.”

• Agios’ mitapivat won priority review in sickle cell despite missing its co-primary VOC endpoint — no AdCom required — and Eric Schmidt reads it as proof “the FDA is open for business” on rare disease. He’d reprice Replimune and Aiolos from 10–20% approval odds to “maybe close to 70 or 80%,” with Regenxbio and peers right-shifted too; Paul is less sweeping — uniQure at ~$40 still prices only about halfway to approval, and “maybe every situation is different.”

• Vertex bought Crinetics for ~$10B ($9B net of cash), a near-100% premium, marking rare endocrinology as the next niche to “get hot.” Paul’s take: the only real risk is atumelnant’s liver signal (seven enzyme elevations, all mild, self-resolving), floor value looks like $1B+ per drug versus Vertex’s claimed $5B combined, and at a $130B cap “this is the kind of stuff they should be doing.” Josh mourns losing an endocrine company with “essentially no target risk.”

• European acquirers are suddenly aggressive: Ipsen paid $450M upfront for Kartos Therapeutics (phase 3 myelofibrosis) and €200M for Memo Therapeutics, while Novartis paid $1.1B cash upfront for preclinical UK ADC company Myricx — “a little bit rich,” so “there must be something really exciting in there.” BridgeBio separately banked a $1B Sixth Street/KKR royalty financing ahead of three launches in 12 months, with the Attruby launch already “exceptional.”

• Herper’s dispatch from Anthropic’s Claude for Science launch: “AI is really cool and nobody knows what to do with it” — but even the mundane case is big. BMS’s Chris Boerner cites “5 to 10% efficiencies but across the board,” and the modest scenario — development time down 30%, success rates from 8% to 16% — is “astounding”: “you don’t have to do what Dario says we’re going to do for things to change a lot.” The unsolved problem: biology lacks coding’s fast feedback loop.

• AAIC’s main event Tuesday: full data on Biogen’s anti-tau ASO, which missed its dose-response primary because the lowest dose did best — yet Biogen is going to phase 3 with two large randomized studies. Paul stays constructive because tau has “the strongest scientific rationale for a disease-modifying target in Alzheimer’s”; the real question is whether the data hands the play to IV brain-shuttle rivals such as Denali and Arrowhead. Eric’s buy-side checks run “9 to one” negative, and both confess “PTSD from Alzheimer’s.”

• Tape check: despite the day’s pullback, the XBI is up 30% YTD and nearly 80% year-over-year — M&A froth is “a dangerous place,” but “industry fundamentals [are] better than they’ve ever been.” Revolution Medicines added another win: G12D-selective zoldonrasib posted 82% ORR/96% DCR with FOLFIRINOX in first-line pancreatic cancer, though Eric says the G12D-plus-pan-RAS combination did not look much better than pan-RAS alone and is unsure there is synergy.

• 🔗 Original source & video: Episode 188 - July 10, 2026

Interview Summary & Key Takeaways: XBI’s rise into the mid-150s is backed by fundamentals, though an AI reversal could create cross-sector downside risk. Josh Schimmer’s regression found an R² of just 0.2 between XBI performance and deal value; AbbVie’s $10.9B Apogee purchase instead highlights replicability and order of entry. FDA normalization and continued China-originated financings are catalysts, while restrictions that compress biotech returns remain a risk.

• 🔗 Original source & video: Episode 187 - June 26, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

• The panel’s verdict on the XBI’s run from the 130–140 range to the mid-150s: warranted, not frothy. Eric Schmidt says the “aren’t we getting ahead of ourselves” question he heard in every European meeting is “PTSD” — fundamentals are “almost a perfect storm” (permissive FDA, M&A, low rates, innovation), and names still drop 20–25% on the week, so it’s “still a good stock picker’s market.” Tess Cameron’s anchor: buying all of smidcap biotech would take a bit under four years of pharma free cash flow, versus over five years at the 2020 top.

• The tail risk investors now fear isn’t biotech-specific — it’s AI. Sam Fazeli: clients are “not just worried about where XBI is going” but what happens if the AI trade — “I’m not going to call it a bubble, but a lot of people do use that phrase” — bursts and drags biotech down with it, a cross-sector fear that “wasn’t necessarily always the case.”

• Josh Schimmer challenged the M&A-drives-biotech orthodoxy with data: his regression of XBI performance versus biopharma deal value over 5–6 years yields an R² of just 0.2, and ~$100B of annual M&A against a ~$1.4T sector may not “move the needle” versus the potential of profitable, independent biotechs attracting generalists. Revolution Medicines is exhibit A — a rumored Merck take-out near $120 never happened and the stock hit $180, with backers now seeing “a future Vertex.” Eric’s counter: $50–100B of deals a year at 40–50% premiums is $20–25B biotech investors “otherwise don’t get access to.”

• AbbVie’s $10.9B Apogee buyout shows why an optimized antibody against a known target can command a major premium over earlier, cheaper China assets. The half-life-extended IL-13 antibody is pitched as a $10B+ peak-sales potential better Dupixent; Tess said she thought this was the first prominent example of the model, while Eric said AbbVie stressed that Part B of Apogee’s trial looked like a global study (“replicability”) and that 2030 sales versus Dupixent’s 2031 atopic-derm loss of exclusivity means “a year maybe worth a lot” — because “order of entry really matters… strategics are willing to pay a lot for that.”

• On China restrictions, Tess’s numbers cut against the panic: 2025’s headline $136B of China out-licensing carried only ~$5.6B of upfronts — less than the single Apogee deal — while ex-China out-licensing has held at $140–160B a year since 2021. Her policy frame: protect physical supply chains, but a ban on innovation supply chains (patent-based) is “self-defeating,” and “a compression of returns in biotech is just going to mean less money for biotech.” Eric’s fatalism: policing what counts as innovation is like “arguing about the weather.”

• Sam declares the FDA “very close to normality”: “Bring your drug, we’ll assess it properly…” The “one year of waste” is being walked back — Moderna’s flu vaccine, REGENXBIO’s resubmitted Hunter BLA, and Replimune’s Q3 oncolytic-virus AdCom — while RBC’s commissioner shortlist is Heidi Overton, John Crowley, Stephen Ferrara, Norm Sharpless, Richard Pops, and Kyle Diamantas; pointedly, “Vinay Prasad is not on the list.”

• The China-newco machine keeps printing: Seraphina reversed YolTech’s in vivo base-editing therapy for AATD (YOLT-202, now SERA-01) into Boundless Bio with a $230M raise co-led by RA and RTW, and Allium Biosciences raised a $330M Series B for Innovent-originated Eylea rival OLN-3024 — triggering a Bob Nelsen–Kolchinsky Twitter spat over copycat innovation. Also flagged: MoonLake’s sonelokimab hit 67.2% HiSCR75 at week 52 in HS versus roughly 60% for bimekizumab, and positive Phase 3 LSD data in MDD kept the interventional-psychiatry wave rolling.

• 🔗 Original source & video: Episode 187 - June 26, 2026

Interview Summary & Key Takeaways: Biotech is outperforming healthcare, with XBI up 10.5% year-to-date and Parabilis Medicines setting a $771M IPO record. Selective capital remains pivotal: Summit withdrew its $500M offering before the binary global HARMONi-3 readout, while Tango and Revolution reported a 90%+ response rate. Major deals and regulatory shifts offer catalysts, but financing needs, commercial competition, and follow-on capital allocation remain unresolved risks.

• 🔗 Original source & video: Episode 186 - June 12, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

• The panel’s verdict on the XBI’s run from the 130–140 range to the mid-150s: warranted, not frothy. Eric Schmidt says the “aren’t we getting ahead of ourselves” question he heard in every European meeting is “PTSD” — fundamentals are “almost a perfect storm” (permissive FDA, M&A, low rates, innovation), and names still drop 20–25% on the week, so it’s “still a good stock picker’s market.” Tess Cameron’s anchor: buying all of smidcap biotech would take a bit under four years of pharma free cash flow, versus over five years at the 2020 top.

• The tail risk investors now fear isn’t biotech-specific — it’s AI. Sam Fazeli: clients are “not just worried about where XBI is going” but what happens if the AI trade — “I’m not going to call it a bubble, but a lot of people do use that phrase” — bursts and drags biotech down with it, a cross-sector fear that “wasn’t necessarily always the case.”

• Josh Schimmer challenged the M&A-drives-biotech orthodoxy with data: his regression of XBI performance versus biopharma deal value over 5–6 years yields an R² of just 0.2, and ~$100B of annual M&A against a ~$1.4T sector may not “move the needle” versus the potential of profitable, independent biotechs attracting generalists. Revolution Medicines is exhibit A — a rumored Merck take-out near $120 never happened and the stock hit $180, with backers now seeing “a future Vertex.” Eric’s counter: $50–100B of deals a year at 40–50% premiums is $20–25B biotech investors “otherwise don’t get access to.”

• AbbVie’s $10.9B Apogee buyout shows why an optimized antibody against a known target can command a major premium over earlier, cheaper China assets. The half-life-extended IL-13 antibody is pitched as a $10B+ peak-sales potential better Dupixent; Tess said she thought this was the first prominent example of the model, while Eric said AbbVie stressed that Part B of Apogee’s trial looked like a global study (“replicability”) and that 2030 sales versus Dupixent’s 2031 atopic-derm loss of exclusivity means “a year maybe worth a lot” — because “order of entry really matters… strategics are willing to pay a lot for that.”

• On China restrictions, Tess’s numbers cut against the panic: 2025’s headline $136B of China out-licensing carried only ~$5.6B of upfronts — less than the single Apogee deal — while ex-China out-licensing has held at $140–160B a year since 2021. Her policy frame: protect physical supply chains, but a ban on innovation supply chains (patent-based) is “self-defeating,” and “a compression of returns in biotech is just going to mean less money for biotech.” Eric’s fatalism: policing what counts as innovation is like “arguing about the weather.”

• Sam declares the FDA “very close to normality”: “Bring your drug, we’ll assess it properly…” The “one year of waste” is being walked back — Moderna’s flu vaccine, REGENXBIO’s resubmitted Hunter BLA, and Replimune’s Q3 oncolytic-virus AdCom — while RBC’s commissioner shortlist is Heidi Overton, John Crowley, Stephen Ferrara, Norm Sharpless, Richard Pops, and Kyle Diamantas; pointedly, “Vinay Prasad is not on the list.”

• The China-newco machine keeps printing: Seraphina reversed YolTech’s in vivo base-editing therapy for AATD (YOLT-202, now SERA-01) into Boundless Bio with a $230M raise co-led by RA and RTW, and Allium Biosciences raised a $330M Series B for Innovent-originated Eylea rival OLN-3024 — triggering a Bob Nelsen–Kolchinsky Twitter spat over copycat innovation. Also flagged: MoonLake’s sonelokimab hit 67.2% HiSCR75 at week 52 in HS versus roughly 60% for bimekizumab, and positive Phase 3 LSD data in MDD kept the interventional-psychiatry wave rolling.

• 🔗 Original source & video: Episode 186 - June 12, 2026

Interview Summary & Key Takeaways: Bristol Myers’ BMS–Hengrui deal gives Hengrui options to co-develop select assets and conduct certain commercialization activities globally, alongside up to $950M in payments and $15.2B potential value. China’s low-cost, high-speed innovation creates licensing opportunity now, but three-to-five-year global-commercialization plans could shift value capture toward Chinese developers; REGENXBIO’s held DMD filing and Biogen’s Phase 3 tau decision keep precedent and capital allocation in focus.

• 🔗 Original source & video: Episode 183 - May 15, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Bristol Myers’ BMS–Hengrui deal gives Hengrui options to co-develop select assets and conduct certain commercialization activities globally, alongside up to $950M in payments and $15.2B potential value. China’s low-cost, high-speed innovation creates licensing opportunity now, but three-to-five-year global-commercialization plans could shift value capture toward Chinese developers; REGENXBIO’s held DMD filing and Biogen’s Phase 3 tau decision keep precedent and capital allocation in focus.

• 🔗 Original source & video: Episode 183 - May 15, 2026

Interview Summary & Key Takeaways: Novo’s CagriSema delivered 12.6% placebo-adjusted weight loss in REDEFINE 2, broadly in line with Zepbound, but the stock fell roughly 8–10%. Policy risks include MFN pricing, tariffs and vaccine trust, while PBM reform, IRA fixes and the tax bill offer upside; a report expected the week of April 7 could be a catalyst.

• 🔗 Original source & video: Episode 134 - March 14, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Novo’s CagriSema delivered 12.6% placebo-adjusted weight loss in REDEFINE 2, broadly in line with Zepbound, but the stock fell roughly 8–10%. Policy risks include MFN pricing, tariffs and vaccine trust, while PBM reform, IRA fixes and the tax bill offer upside; a report expected the week of April 7 could be a catalyst.

• 🔗 Original source & video: Episode 134 - March 14, 2025

Interview Summary & Key Takeaways: AI may have delivered only 10–15% of its eventual impact, while software development has shifted from assisted coding to autonomous orchestration within months.citeturn0search0 Recursive self-improvement remains two to three years away in San Francisco’s consensus but does not yet work, while a projected 92-gigawatt US power shortfall by 2030 makes electricity the key constraint to monitor.

• 🔗 Original source & video: Eric Schmidt on the Robotics Race, Singularity Timeline, and Energy Shortage | 241
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: AI may have delivered only 10–15% of its eventual impact, while software development has shifted from assisted coding to autonomous orchestration within months.citeturn0search0 Recursive self-improvement remains two to three years away in San Francisco’s consensus but does not yet work, while a projected 92-gigawatt US power shortfall by 2030 makes electricity the key constraint to monitor.

• 🔗 Original source & video: Eric Schmidt on the Robotics Race, Singularity Timeline, and Energy Shortage | 241

Interview Summary & Key Takeaways: Biotech posted its strongest IPO quarter in four years, with $2B of Q1 IPOs and a $2.5B run rate. Roivant’s Moderna settlement could reach $2.25B, with $950M cash in July and up to $1.3B tied to the §1498 appeal. Paying the contingent amount could leave roughly “two and change” years of cash, while GLP-1 orals broaden a $100B market and threaten consumer categories.

• 🔗 Original source & video: Episode 175 - March 6, 2026
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Biotech posted its strongest IPO quarter in four years, with $2B of Q1 IPOs and a $2.5B run rate. Roivant’s Moderna settlement could reach $2.25B, with $950M cash in July and up to $1.3B tied to the §1498 appeal. Paying the contingent amount could leave roughly “two and change” years of cash, while GLP-1 orals broaden a $100B market and threaten consumer categories.

• 🔗 Original source & video: Episode 175 - March 6, 2026

Interview Summary & Key Takeaways: Biotech’s year-end pause looks like healthy stock-picker consolidation, with XBI near 124 while mediocre data from Pyxis and Nektar were heavily punished. Nearly $9B of October-November follow-ons is creating indigestion, as first-day performance increasingly sets discounts for subsequent deals. Confidential S-1 flips could fuel a Q1 IPO rush, but recycled issuers and a disrupted FDA policy backdrop make quality and execution the key risks.

• 🔗 Original source & video: Episode 167 - December 19, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Biotech’s year-end pause looks like healthy stock-picker consolidation, with XBI near 124 while mediocre data from Pyxis and Nektar were heavily punished. Nearly $9B of October-November follow-ons is creating indigestion, as first-day performance increasingly sets discounts for subsequent deals. Confidential S-1 flips could fuel a Q1 IPO rush, but recycled issuers and a disrupted FDA policy backdrop make quality and execution the key risks.

• 🔗 Original source & video: Episode 167 - December 19, 2025

Interview Summary & Key Takeaways: Eric Schmidt expects America to retain the top-end AGI lead while China embeds AI everywhere and dominates inexpensive physical systems, including Unitree’s $6,000 R1; electricity, not chips, may become America’s binding constraint. Falling compute costs and open Chinese models weaken static controls and could establish global standards through price, while biology remains the catalyst most likely to force coordinated policy and a major test of startup defensibility.

• 🔗 Original source & video: Ex-Google CEO Breaks Down the US vs. China AI Race & How We Avoid a Global Crisis w/ Dr. Eric Schmidt & Dave Blundin | EP #207
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Eric Schmidt expects America to retain the top-end AGI lead while China embeds AI everywhere and dominates inexpensive physical systems, including Unitree’s $6,000 R1; electricity, not chips, may become America’s binding constraint. Falling compute costs and open Chinese models weaken static controls and could establish global standards through price, while biology remains the catalyst most likely to force coordinated policy and a major test of startup defensibility.

• 🔗 Original source & video: Ex-Google CEO Breaks Down the US vs. China AI Race & How We Avoid a Global Crisis w/ Dr. Eric Schmidt & Dave Blundin | EP #207

Interview Summary & Key Takeaways: Schmidt puts true ASI beyond the industry’s “San Francisco consensus” of three to four years, even as compounding gains could pull the date forward. He defines it as intelligence equal to “the sum of everyone” or better than all humans, but today’s systems cannot quickly feed newly learned reasoning back into themselves; creative superintelligence may…

• 🔗 Original source & video: Part 1: Eric Schmidt and Fei-Fei Li: Human Life After Artificial Superintelligence | EP #206
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Schmidt puts true ASI beyond the industry’s “San Francisco consensus” of three to four years, even as compounding gains could pull the date forward. He defines it as intelligence equal to “the sum of everyone” or better than all humans, but today’s systems cannot quickly feed newly learned reasoning back into themselves; creative superintelligence may…

• 🔗 Original source & video: Part 1: Eric Schmidt and Fei-Fei Li: Human Life After Artificial Superintelligence | EP #206

Interview Summary & Key Takeaways: Biotech’s tape has turned: XBI rose 11.9% versus 2% for the S&P over the past month. Sanofi’s 10% drop after amlitelimab met its primary endpoint highlights Dupixent’s expected $2.5B 2030 sales and 2031 patent loss. Fall HARMONi OS, FLAURA-2 OS and neuro readouts hinge on confidence intervals, China/ex-China consistency, screening failure and regulatory flexibility.

• 🔗 Original source & video: Episode 153 - September 5, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Biotech’s tape has turned: XBI rose 11.9% versus 2% for the S&P over the past month. Sanofi’s 10% drop after amlitelimab met its primary endpoint highlights Dupixent’s expected $2.5B 2030 sales and 2031 patent loss. Fall HARMONi OS, FLAURA-2 OS and neuro readouts hinge on confidence intervals, China/ex-China consistency, screening failure and regulatory flexibility.

• 🔗 Original source & video: Episode 153 - September 5, 2025

Interview Summary & Key Takeaways: Schmidt now expects China’s chip constraints and shallower capital markets to favor ubiquitous AI deployment, while open weights and training data could make model distribution a geopolitical contest that America must not concede. Cheap autonomous drones are overturning defense economics, with a $4,000-$5,000 aircraft carrying a 2-kilogram payload able to destroy a $30 million tank, raising unresolved questions about deterrence and escalation.

• 🔗 Original source & video: Eric Schmidt on AI, the Battle with China, and the Future of America
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Schmidt now expects China’s chip constraints and shallower capital markets to favor ubiquitous AI deployment, while open weights and training data could make model distribution a geopolitical contest that America must not concede. Cheap autonomous drones are overturning defense economics, with a $4,000-$5,000 aircraft carrying a 2-kilogram payload able to destroy a $30 million tank, raising unresolved questions about deterrence and escalation.

• 🔗 Original source & video: Eric Schmidt on AI, the Battle with China, and the Future of America

Interview Summary & Key Takeaways: AI’s next constraint may be electricity rather than chips, with Eric Schmidt estimating the US needs another 92 GW as reasoning and test-time compute consume efficiency gains. His aggressive timeline points to world-class AI mathematicians within one year, programmers within one or two, and digital superintelligence within 10, while enterprise software, jobs, China, and AI security remain unresolved.

• 🔗 Original source & video: Ex-Google CEO: What Artificial Superintelligence Will Actually Look Like w/ Eric Schmidt & Dave B
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: AI’s next constraint may be electricity rather than chips, with Eric Schmidt estimating the US needs another 92 GW as reasoning and test-time compute consume efficiency gains. His aggressive timeline points to world-class AI mathematicians within one year, programmers within one or two, and digital superintelligence within 10, while enterprise software, jobs, China, and AI security remain unresolved.

• 🔗 Original source & video: Ex-Google CEO: What Artificial Superintelligence Will Actually Look Like w/ Eric Schmidt & Dave B

Interview Summary & Key Takeaways: Vinay Prasad’s CBER appointment erased 7% from XBI in a day, but his conciliatory debut shifted the key signal from rhetoric to approvals. MRD as a myeloma filing endpoint is the live test: a reversal could lengthen cell-therapy trials, while CDER bispecifics may retain it. Sarepta’s guidance cut to $2.3–2.6B exposed capacity risk, while Novavax and a possible MFN order leave regulatory and pricing catalysts unresolved.

• 🔗 Original source & video: Episode 141 - May 9, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Vinay Prasad’s CBER appointment erased 7% from XBI in a day, but his conciliatory debut shifted the key signal from rhetoric to approvals. MRD as a myeloma filing endpoint is the live test: a reversal could lengthen cell-therapy trials, while CDER bispecifics may retain it. Sarepta’s guidance cut to $2.3–2.6B exposed capacity risk, while Novavax and a possible MFN order leave regulatory and pricing catalysts unresolved.

• 🔗 Original source & video: Episode 141 - May 9, 2025

Interview Summary & Key Takeaways: FDA instability now outweighs tariffs as biotech’s central risk, with Peter Marks’s resignation and layoffs leaving its direction unclear. Ultragenyx, REGENXBIO and Denali will test whether prior FDA agreements and CSF heparan sulfate-based accelerated-approval pathways hold, while Lilly’s lepodisiran cut Lp(a) 93.5% at six months. Pelacarsen’s outcomes readout moves to the first half of next year.

• 🔗 Original source & video: Episode 137 - April 4, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: FDA instability now outweighs tariffs as biotech’s central risk, with Peter Marks’s resignation and layoffs leaving its direction unclear. Ultragenyx, REGENXBIO and Denali will test whether prior FDA agreements and CSF heparan sulfate-based accelerated-approval pathways hold, while Lilly’s lepodisiran cut Lp(a) 93.5% at six months. Pelacarsen’s outcomes readout moves to the first half of next year.

• 🔗 Original source & video: Episode 137 - April 4, 2025

Interview Summary & Key Takeaways: Twice-yearly lenacapavir could drive Gilead’s PrEP revenue toward about $4 billion by 2030; CDC spending near $1.3 billion makes policy a valuation variable. Immunovant’s 680 mg batoclimab cut MG-ADL 5.6 versus 3.6 for placebo, keeping IMVT-1402 differentiation under debate. DMD exon skippers reached 10–25% dystrophin and near-normal CK, but functional benefit and AAV risk remain unresolved.

• 🔗 Original source & video: Episode 135 - March 21, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Twice-yearly lenacapavir could drive Gilead’s PrEP revenue toward about $4 billion by 2030; CDC spending near $1.3 billion makes policy a valuation variable. Immunovant’s 680 mg batoclimab cut MG-ADL 5.6 versus 3.6 for placebo, keeping IMVT-1402 differentiation under debate. DMD exon skippers reached 10–25% dystrophin and near-normal CK, but functional benefit and AAV risk remain unresolved.

• 🔗 Original source & video: Episode 135 - March 21, 2025

Interview Summary & Key Takeaways: Novo Nordisk’s 8–10% selloff after REDEFINE 2 may overemphasize CagriSema’s 12.6% placebo-adjusted loss, while dosing flexibility, tolerability and safety could shape commercial outcomes. Policy uncertainty around MFN, tariffs, vaccines and China, plus April 7 week proposals, March 28 BioNTech data and Legend’s capacity expansion, puts durable reform and execution in focus.

• 🔗 Original source & video: Episode 134 - March 14, 2025
• 📝 Transcript Status: Core insights and takeaways summarized. Full runtime is approx 45-90 mins.

Key Takeaways: Novo Nordisk’s 8–10% selloff after REDEFINE 2 may overemphasize CagriSema’s 12.6% placebo-adjusted loss, while dosing flexibility, tolerability and safety could shape commercial outcomes. Policy uncertainty around MFN, tariffs, vaccines and China, plus April 7 week proposals, March 28 BioNTech data and Legend’s capacity expansion, puts durable reform and execution in focus.

• 🔗 Original source & video: Episode 134 - March 14, 2025